Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Item

http://www.wikidata.org/entity/Q41356235

Q41356235

about

Long-term follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: subset analysis of the NHL-003 study.Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia.Lenalidomide inhibits the proliferation of CLL cells via a cereblon/p21(WAF1/Cip1)-dependent mechanism independent of functional p53 Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia.Cytokine expression profiles of immune imbalance in post-mononucleosis chronic fatigue.Combining immunotherapy and targeted therapies in cancer treatment.Lenalidomide alone and in combination for chronic lymphocytic leukemia.Isotype-specific inhibition of the phosphatidylinositol-3-kinase pathway in hematologic malignancies.Rethinking clinical response and outcome assessment in a biologic age.AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.Paradoxical effect of lenalidomide on cytokine/growth factor profiles in multiple myeloma.Molecular action of lenalidomide in lymphocytes and hematologic malignancies CC-122 immunomodulatory effects in refractory patients with diffuse large B-cell lymphoma.Combination of lenalidomide with vitamin D3 induces apoptosis in mantle cell lymphoma via demethylation of BIK.Long-term molecular remission with lenalidomide treatment of relapsed chronic lymphocytic leukemia.Leveraging natural killer cells for cancer immunotherapy.The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs.Evaluation of thrombosis-related biomarkers before and after therapy in patients with multiple myeloma.Extended B cell phenotype in patients with myalgic encephalomyelitis/chronic fatigue syndrome: a cross-sectional study.Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide.Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma.Critical molecular pathways in CLL therapy.Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T-cells in chronic lymphocytic leukemia

P2860

Q33410282-619EFDBB-F0AB-4158-8C08-F567127A1247 Q33418964-F3F788D7-9FC1-4977-8977-F862343199B4 Q34009003-8DFEF51D-32FB-4FBD-88FE-0F20BC443FD2 Q34137016-73FB7543-6BA2-4F9E-BA3E-03C8790FE267 Q34278096-A93FBA24-38FD-414E-B684-03B5EAA8321D Q36135185-A97F53FE-4999-4DF3-AA95-7FC18BF8C865 Q36346397-597131D7-6B50-49E7-AA6C-1483ED989F08 Q37995939-90D726B7-52DF-46E2-8840-52AC1A76DAD9 Q38068736-67142D7D-1941-4D7D-8F64-5BADE8A8CFD5 Q38193070-8D60106E-2601-4786-8764-1A405186F7C3 Q38480777-AB300DB2-4E16-484F-89A9-9B9D735A2FA4 Q39062888-E889A38C-4E34-4457-9453-28EFE3D9AB99 Q39158096-4C8E1260-7A74-438A-A9E5-2AB015AECD3F Q39570166-607CB735-8CFD-464E-A484-3B488DA4C496 Q41728843-CDA39A40-6EBE-4661-A0E7-4356000D29E6 Q42111039-BFAEAE68-4995-49C7-9763-FEA9BF34F950 Q43596419-F9B482C7-F25D-428D-BB22-A64D82CC6CE4 Q43865719-7FB3E89E-D36D-42C2-A1C5-C92A81D3EDFB Q45172522-753D556A-6E03-4B1D-A89C-613682677E49 Q50197484-A67323AA-A5A0-4FB0-B788-8BD0D5B85EA0 Q50689763-2E1E9AF1-97A8-4603-B9E4-2940B2DD812A Q50864223-781EBB35-4AA5-4855-AC37-64E9B97AB73B Q51051144-D4A9C503-DC4F-4285-A4FB-86188E789614 Q55447785-2A545757-580F-4A60-9033-EF6FBF56A7C2 Q57807709-51E3028E-2F56-4DDE-8FF5-5FE839E46F63

P2860

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

Item

http://www.wikidata.org/entity/Q41356235

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Biological effects and clinica ...... ation and antitumour response.

@en

type

Item

label

Biological effects and clinica ...... ation and antitumour response.

@en

prefLabel

Biological effects and clinica ...... ation and antitumour response.

@en

P1476

Biological effects and clinica ...... ation and antitumour response.

@en

P2093

Abhisek Swaika

http://www.w3.org/2001/XMLSchema#string

Aisha Masood

http://www.w3.org/2001/XMLSchema#string

Aneel Paulus

http://www.w3.org/2001/XMLSchema#string

Asher A Chanan-Khan

http://www.w3.org/2001/XMLSchema#string

Greg Wilding

http://www.w3.org/2001/XMLSchema#string

Ivan Borrello

http://www.w3.org/2001/XMLSchema#string

Kasyapa Chitta

http://www.w3.org/2001/XMLSchema#string

Kelvin Lee

http://www.w3.org/2001/XMLSchema#string

Myron S Czuczman

http://www.w3.org/2001/XMLSchema#string

Naveen Bangia

http://www.w3.org/2001/XMLSchema#string

P2860

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.

Efficacy of lenalidomide in myelodysplastic syndromes.

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells.

P304

457-467

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1365-2141.2011.08882.X

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

155

http://www.w3.org/2001/XMLSchema#string

P577

2011-10-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51729844

http://www.w3.org/2001/XMLSchema#string

P698

22010965

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

lymphocyte

P932

3698616

http://www.w3.org/2001/XMLSchema#string

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

about

P2860

P2860

Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P5875

P698

P921

P932